Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sciformix Awarded Pharmaceutical KPO Entrepreneurial Company of the Year

Published: Thursday, July 18, 2013
Last Updated: Wednesday, July 17, 2013
Bookmark and Share
Company has received this prestigious award from Frost & Sullivan.

Sciformix Corporation has announced that it has received Frost & Sullivan’s prestigious Pharmaceutical Knowledge Process Outsourcing (KPO) Entrepreneurial Company of the Year award.

Based on its recent analysis of the pharmaceutical sourcing market, Frost & Sullivan recognizes Sciformix for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic service development.

Each year, Frost & Sullivan presents this award to the company that has demonstrated entrepreneurial spirit by devising a strong growth strategy and robustly implementing it.

Sciformix has shown strength in terms of innovation in business processes, leadership in customer value as well as market penetration.

The award looks at the emerging market players in the industry and recognizes their best practices that are positioned for future growth excellence.

Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best-practice organizations.

The award recognizes Sciformix as a unique, scientific, knowledge-based company among KPO organizations with regard to its depth and breadth of Life Science expertise in supporting its clients through the entire drug development cycle to provide a broad range of services, from study design to post-marketing surveillance and commercialization support.

Its unique client-centric and flexible business model spans client needs from niche requests to end-to-end support, and its global talent pool of PhDs, doctors, pharmacists, statisticians, programmers, medical writers, regulatory affairs and TA experts afford Sciformix the ability to adapt to the constantly changing healthcare and life sciences environment.

The award was benchmarked against strict criteria, which saw Sciformix outperforming its competitors. These include growth strategy excellence, growth implementation excellence, degree of innovation with products and technologies, leadership in customer value and speed of response to market needs.

One of the reasons Sciformix was awarded this honor was because of its ability to fill the gaps left by Business Process Organizations (BPOs) and Contract Research Organizations (CROs) who may focus more on operations and less on science, or more on science and not as much on processes, or larger multi- industry organizations that lack the advantage of specialized Life Science expertise.

Sciformix is also recognized because it has attracted an extensive pool of talent with diverse capabilities and abundant subject-matter expertise in all phases of drug development, from initiation of clinical trials to post-marketing support, and its ability to tailor flexible solutions to help clients quickly, efficiently and safely bring drugs to the market and manage the product lifecycle after approval.

“It is a great achievement for Sciformix to receive this prestigious award and be recognized for our entrepreneurship and commitment to innovation. We are investing in our people to encourage our talented employees to consistently develop and apply innovative ideas and approaches,” said Ajit Nagral, executive chairman of Sciformix Corporation.

In addition, “Our client-focused and flexible business model ensures that we provide expertise in both science and operations to our clients, delivering the best possible outcomes for patients and manufacturers in regard to safety and efficacy of drugs.”

Sciformix’s mission is to partner with global Life Science companies to provide high-quality, scientific, knowledge-based expertise that delivers better quality outcomes and improved efficiencies across the entire product lifecycle with the ultimate objective of improving quality of healthcare for patients worldwide.

Areas of specialization include Safety and Risk Management, Clinical Research and Post-Approval Service Support, Medical Affairs, Scientific Writing and Regulatory Affairs.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sciformix Corporation CSO Honoured in PharmaVOICE 100
Dr. Chitra Lele is recognized for pioneering work in service provision across global markets.
Friday, August 01, 2014
Sciformix Executives Drive Agenda on Achieving Drug Safety Excellence at World Drug Safety Congress
5th Annual World Drug Safety Congress to be held from April 24 - 25, 2013 at Boston, USA.
Thursday, March 28, 2013
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!